NasdaqGM - Delayed Quote • USD
ANI Pharmaceuticals, Inc. (ANIP)
At close: April 24 at 4:00 PM EDT
After hours: April 24 at 4:02 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Nikhil Lalwani | President, CEO & Director | 2.32M | 373.22k | 1978 |
| Mr. Stephen P. Carey | Senior VP of Finance & CFO | 1.11M | -- | 1971 |
| Mr. Chad Gassert | Senior Vice President of Corporate Development & Strategy | 849.71k | -- | 1976 |
| Mr. Christopher K. Mutz | Senior Vp & Head of Rare Disease | 867.92k | -- | 1972 |
| Mr. Ori Gutwerg | Senior Vice President of Generics | 895.16k | 436.25k | 1975 |
| Mr. Muthusamy Shanmugam MS R.Ph. | Head of R&D, COO of Novitium Operations & Director | -- | -- | 1968 |
| Mr. James G. Marken | Senior Vice President of Operations & Product Development | 673.23k | -- | 1963 |
| Ms. Meredith W. Cook | Senior VP, General Counsel & Corporate Secretary | -- | -- | 1975 |
| Ms. Krista L. Davis | Senior VP & Chief Human Resources Officer | -- | -- | 1974 |
| Ms. Elizabeth Powell J.D. | Chief Compliance Officer & Head of Legal of Rare Disease | -- | -- | -- |
ANI Pharmaceuticals, Inc.
210 Main Street West
Baudette, MN 56623
United States
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 642
Description
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Corporate Governance
ANI Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 6; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Apr 17, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 05, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 12, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 29, 202410-K: Periodic Financial ReportsSee Full Filing
- Feb 23, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
May 10, 2024
ANI Pharmaceuticals, Inc. Earnings Call
Related Tickers
COLL Collegium Pharmaceutical, Inc.
35.48
-1.28%
CRDL Cardiol Therapeutics Inc.
1.7600
-4.35%
AMRX Amneal Pharmaceuticals, Inc.
6.05
+12.04%
ETON Eton Pharmaceuticals, Inc.
3.2100
-2.13%
ALKS Alkermes plc
24.65
+1.61%
IRWD Ironwood Pharmaceuticals, Inc.
8.10
-2.53%
SUPN Supernus Pharmaceuticals, Inc.
30.26
+1.04%
EGRX Eagle Pharmaceuticals, Inc.
4.5500
-4.61%
PETQ PetIQ, Inc.
16.53
-0.42%
PAHC Phibro Animal Health Corporation
12.56
-7.71%